Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, Georgia, USA.
Curr Opin Psychiatry. 2011 Mar;24(2):122-7. doi: 10.1097/YCO.0b013e3283436eb7.
To review the role of brain-derived neurotrophic factor (BDNF) in neuroplasticity related to schizophrenia and the recent findings that have been reported on the status of BDNF in patients with schizophrenia and its association with the clinical measures.
Peripheral BDNF levels have been found altered in first-episode patients with psychosis and also in chronic schizophrenia patients. A few studies have reported changes in peripheral BDNF levels following antipsychotic treatment. The role of Val66Met polymorphism in BDNF has been shown to play an important role in structural and functional plasticity in schizophrenia.
Although peripheral BDNF levels hold promise for providing new perspectives for the development of novel therapeutic strategies for the treatment of schizophrenia, additional studies including efforts to prove its potential as a biomarker are warranted.
探讨脑源性神经营养因子（BDNF）在与精神分裂症相关的神经可塑性中的作用，以及最近报道的精神分裂症患者 BDNF 状态及其与临床指标的关系的研究结果。
在首发精神病患者和慢性精神分裂症患者中，外周 BDNF 水平发生改变。少数研究报告了抗精神病治疗后外周 BDNF 水平的变化。BDNF 的 Val66Met 多态性在精神分裂症的结构和功能可塑性中起着重要作用。
虽然外周 BDNF 水平为开发治疗精神分裂症的新治疗策略提供了新的视角，但仍需要进一步研究，包括证明其作为生物标志物的潜力。
